SPLX, a Zscaler Company
AI NativeThe end-to-end platform to test, protect, and govern AI at enterprise scale
Published Oct 12, 2026
Direct competitors and key differentiators
Feature comparison: where SPLX may excel vs lag behind
Pricing comparison: value proposition vs alternatives
Customer testimonials comparing SPLX to competitors
Market share and adoption trends
When customers choose competitors instead (and why)
—
| Aspect | SPLX | Protect AI | Mindgard |
|---|---|---|---|
| Starting Price | Public marketplace listing for a red-teaming module with a trial and published tiered professional/enterprise pricing available from the vendor (trial plus published professional and enterprise tiers) | Public pricing not standardized; third-party sources indicate variable pricing and should be validated directly with the vendor | Sales-led; pricing not publicly posted (contact required) |
| Suitable For | Enterprises seeking a combined approach to asset discovery, automated red teaming, runtime guardrails, and governance, and organizations evaluating agent workflow visibility | Teams seeking broader ML/AI security coverage across model scanning, supply chain, red teaming, and runtime controls | Organizations focused on robustness, threat modeling, red teaming, and monitoring with emphasis on technical analysis |
| Key Strength | Emphasis on continuous automated red teaming and agent workflow scanning, plus open-source workflow tooling to aid discovery and adoption; now part of a larger acquirer which can affect distribution and integration pathways | Broad platform positioning across multiple AI/ML security layers per vendor/secondary descriptions | Earlier entrant focusing on robustness and monitoring features (positioning reported in comparison sources) |
| Key Weakness | Limited independent review volume publicly available; limited publicly documented enterprise IAM and data residency detail; post-acquisition integration risks to validate | Pricing and packaging complexity reported by third-party sources; commercial terms vary | Public documentation and independent review coverage may be limited; requires proof of efficacy in POCs |